Zacks Investment Research Lowers Ablynx N.V. (ABLYF) to Sell
Zacks Investment Research downgraded shares of Ablynx N.V. (NASDAQ:ABLYF) from a hold rating to a sell rating in a report published on Monday.
According to Zacks, “Ablynx NV is a biopharmaceutical company which engaged in the development of Nanobodies (R) proprietary therapeutic proteins based on single-domain antibody fragments. The company also discovers and develops therapeutic for inflammation, haematology, immuno-oncology, oncology and respiratory disease. Ablynx NV is headquartered in Ghent, Belgium. “
Shares of Ablynx N.V. (ABLYF) opened at 18.36 on Monday. Ablynx N.V. has a 12-month low of $9.10 and a 12-month high of $50.00. The company’s 50-day moving average is $14.88 and its 200-day moving average is $13.31. The company’s market capitalization is $1.11 billion.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ablynx N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ablynx N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.